**Core tip:** Acute liver diseases induced by viral infections are considered major causes of liver failure and death in Brazil. To better understand this pathogenesis, we investigated in a pioneering way the cellular immune response, inflammatory mediators and mitochondrial products in patients with hepatitis A virus (HAV)-induced acute liver failure (ALF) in comparison to patients with non-virus-induced ALF in a cross-sectional study. The results showed that non-invasive samples could be helpful to assay early prognostic markers that would indicate the necessity for liver transplantation. The contribution of *in vitro* immune response involved in ALF can be helpful to show the necessity of mass vaccination against HAV.

INTRODUCTION
============

Acute liver failure (ALF) is a rare (0.5%-1% of the acute hepatitis cases) and devastating clinical syndrome resulting from an acute insult that occurs when a high percentage of liver cells are rapidly lost. Liver transplantation is the only effective therapy\[[@B1]-[@B4]\]. Non-invasive methods have been proposed to evaluate the liver damage\[[@B5]-[@B7]\] and predict the worst outcome (death)\[[@B8]-[@B10]\], with little success. Nevertheless, there are few studies on the systemically released inflammatory products that indicate liver failure or regeneration before liver transplantation, such as cytokine profile or mitochondrial DNA\[[@B11]-[@B15]\]. Additional early prognostic markers are urgently requested to evaluate the necessity of liver transplantation therapy.

The causes of ALF involve a variety of toxic, viral, metabolic, and vascular liver injuries. The etiology of ALF varies with geography\[[@B16]\], and the hepatitis A virus (HAV) is the major cause of acute hepatitis in Brazil\[[@B17],[@B18]\] due to absence of an effective hepatitis A vaccination program. Recent studies have shown high counts of natural killer (NK) cells (NK^bright^ and NK^dim^) during self-limited hepatitis A\[[@B19]\]. Functionally, NK cells are important components of liver immunology, mediating pro-inflammatory functions, such as IFNγ secretion by NK^bright^ (CD3^-^CD56^+^CD16^-^) cells, as well as the lysis of target cells by a subset of NK^dim^ (CD3^-^CD56^low^ CD16^+^) cells\[[@B7],[@B19]-[@B22]\].

Perrella et al\[[@B23]\] (2008) showed that regulatory T cells (TReg) (CD4^+^CD25^+^) are important factors in acute hepatitis A resolution. Trujillo-Ochoa et al\[[@B14]\] showed that serum IL-17 is elevated in children with acute hepatitis A infection; however, the involvement of TReg and helper T cells in ALF caused by hepatitis A is unknown.

The goal of our study was to evaluate plasma levels of inflammatory and anti-inflammatory cytokines and mtDNA in a pilot study with a case series of liver injury patients and their association with ALF and occurrence of death. We quantified the mechanism of viral (HAV) and non-viral liver dysfunction by phenotypically characterizing cytotoxic, helper, and TReg and analyzed the cytokine secretion in a peripheral blood mononuclear cell (PBMC) clonal proliferation assay.

MATERIALS AND METHODS
=====================

Patients and samples
--------------------

Eighty-four subjects agreed in participate in this study in Rio de Janeiro, Brazil, from 2009 to 2012: 46 (54.76%) were consecutive outpatients with self-limited acute hepatitis (AH) that were referred to the Viral Hepatitis Clinic of Oswaldo Cruz Institute - Fiocruz; 16 (19.05%) inpatients were admitted to the Bonsucesso Federal Hospital, a referral hospital for patients with ALF requiring transplantation; and 22 (26.19%) were healthy donors.

All samples were assayed for HAV, hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis E virus (HEV) serological markers using commercially available enzyme-linked immunoassays (ELISAs): Anti-HAV IgM (Abbott, United States), Vikia HBsAg (Biomerieux, France), Murex anti-HCV version 4.0 (Diasorin, South Africa), and bioELISA HEV IgM version 3.0 (Biokit, Spain). Blood samples were also assayed using rapid tests for syphilis (DPP^®^, Bio-manguinhos, Brazil), HIV-1/2 (DPP^®^, Bio-manguinhos, Brazil), dengue (SD BIOLINE, Standard Diagnostics, South Korea), and leptospirosis (SD BIOLINE, Standard Diagnostics, South Korea). Other current infections and autoimmune diseases were analyzed with a chemiluminescent ELISA for Epstein-Barr, cytomegalovirus and antinuclear antibodies (ANA). The respective reference levels of ≥ 20U/mL, ≥ 30 UA/mL, and ≥ 1.5 UI/mL were considered positive. Herpes virus type 1 (HSV-1) and herpes virus type 2 (HSV-2) were investigated using a TaqMan-based multiplex assay as previously described\[[@B24]\]. Metabolic disorders were also investigated whether the routine exams (biochemical, hematological, *etc*.) presented alterations or whether the patient had a family history of metabolic disorders.

AH cases were defined by aminotransferase levels of at least 10 × the upper normal limit and the onset of jaundice in a previously healthy individual\[[@B25]\]. The cases were further categorized according to international normalized ratio (INR) and hepatic encephalopathy grade (HE). Cases with INR \< 1.5 and no HE were classified as self-limited AH and those with INR ≥ 1.5 and an HE score above II as ALF\[[@B4]\].

The timing of sample collection was based on the onset of jaundice and liver enzyme levels for self-limited AH patients. In ALF patients, the timing of sample collection was based on ALF diagnosis and hospital admission. In healthy subjects, the sample collection was based on the lack of infection found in their routine exams.

The study population was divided into five groups according to etiology and clinical condition: Group 1: Virus-induced self-limited hepatitis, of which all cases were caused by HAV-AH; group 2: Non-viral-induced self-limited hepatitis, which included drug and indeterminate causes (non-viral AH); group 3: Virus-induced ALF, of which all cases were caused by HAV-ALF; group 4: Non-viral-induced ALF, which included drug and indeterminate causes (non-viral ALF); and group 5: Healthy subjects, as the control group (HC).

To assess the PBMCs, blood samples were collected in the anticoagulant citrate-dextrose solution-A (Greiner Bio-one, Kremsmünster, Austria) and stored at -70 °C (plasma) or in liquid nitrogen (peripheral blood mononuclear cells, PBMCs) until assay. Plasma and PBMC samples used were thawed only once for the different assays.

The study protocol was approved by the National Commission on Ethics in Research (CONEP), and by the institutional review board of the Oswaldo Cruz Foundation, FIOCRUZ (222/03). Signed informed consent was obtained from all participants. The study was performed in compliance with the relevant laws and institutional guidelines and in accord with the ethical standards of the Declaration of Helsinki.

Quantitative detection of cytokines and mitochondrial-derived DNA in ALF, AH and healthy control subjects
---------------------------------------------------------------------------------------------------------

To assess the liver inflammatory/anti-inflammatory status, plasma levels of the cytokines IL-6, IL-8, IL-10, IFNγ and tumor necrosis factor alpha (TNFα) were quantified using commercially available Standard ELISA Development kits (Peprotech, United States). To assess hepatocellular damage, the total DNA was purified from the plasma samples using the QIAamp DNA Blood Mini Kit (Qiagen, United States) according to the manufacturer's instructions\[[@B26]\]. The mitochondrial DNA (mtDNA) was quantified by real-time PCR as previously reported\[[@B26]\] using 3 pairs of primers specific for human cytochrome B (sense 5'atgaccccaatacgcaaaat-3' and antisense 5'cgaagtttcatcatgcggag3'), human cytochrome C oxidase subunit III (sense 5'atgacccaccaatcacatgc3' and antisense 5'atcacatggctaggccggag3'), and human NADH dehydrogenase (sense 5'atacccatggccaacctcct3' and antisense 5'gggcctttgcgtagttgtat3'). The total mtDNA value corresponds to the sum of the individual values from each test. Colorimetric commercial kits were used to assess the levels of liver enzymes and total bilirubin.

Quantitative evaluation of the clonal proliferation response and cell phenotypes of proliferated PBMCs from ALF and AH patients
-------------------------------------------------------------------------------------------------------------------------------

Twenty-nine PBMC samples from 62 patients were evaluated for the proliferative cellular immune response: 16 samples from patients with self-limited AH (8 patients diagnosed with HAV-induced hepatitis and 8 with non-viral hepatitis) and 13 samples from patients with ALF (8 patients diagnosed with HAV-induced hepatitis and 5 with non-viral hepatitis). Ten of twenty-two healthy subject samples were included in the cellular response assay.

The PBMCs from each patient were separated on a Ficoll density gradient by centrifugation (30 min at 400 g at 18 °C). The concentration of viable cells was determined by trypan blue exclusion. Samples with less than 80% of viable cells at this stage were excluded. In the proliferation assay, the PBMCs were suspended in RPMI 1640 (Sigma Aldrich, United States) medium at a concentration of 5 × 10^6^ cells/mL and mixed with an equal volume of 10 mmol/L carboxyfluorescein succinimidyl ester working solution (CFSE-FITC) (Molecular Probes, Invitrogen, United States) that was diluted 1/1000 for all analyses. Cells that were not labeled with CFSE were used as a negative control for the flow cytometry analysis. The mitogen inducers phytohemagglutinin (PHA) and lipopolysaccharide (LPS) (Sigma Aldrich, United States) were used at final concentrations of 10 μg/mL and 1 ng/mL, respectively, for non-viral proliferation. The HAF-203 strain of HAV was propagated in FRhK-4 cells\[[@B27]\] and was used for viral-antigen-specific (HAV Ag) proliferation (viral titer of 10^6^ HAV-RNA/mL). Duplicate proliferation cultures were performed with 5 × 10^5^ cells/well in 96-well flat bottom culture plates. The plates were incubated at 37 °C in a 5% CO~2~ incubator for 72 h with PHA, 24 h with LPS and 96 h with HAV Ag. After incubation, the cells were harvested for the flow cytometry assay.

To assess the cell phenotypes and proliferative response, 20000 live cells were collected from each sample using a Cyan flow cytometer (BD Biosciences, United States) and analyzed using the off-line software Summit version 6.0 (Dako Cytomation, United States) (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). PBMCs were labeled and quantified with αCD8-PerCP (clone DK25), αCD25-PE (clone ACT1), αCD56-PE (clone CM55B), αCD16-FITC (clone DJ130c) (all from Dako Cytomation, United States), αCD3-APC (clone OKT3), αCD29-FITC (clone MEM101a), αCD44-PECy7 (clone IM7), αFoxP3-FITC (clone PCH101) and isotypes (eBiosciences, San Diego, CA, United States). The intracellular staining for FoxP3 expression was performed with a Cytofix/Cytoperm^®^ kit (BD Biosciences, United States). Total mononuclear cells were electronically gated in R1 *plus* R2 using forward (FSC) and side (SSC) properties; cellular debris and granular cells were excluded (Figure [1A](#F1){ref-type="fig"} and B). The proliferating cells (R1 + R2) were defined based on their FSC and SSC properties\[[@B28]\]. The proliferation index (PI) was determined by the software program; this index is a measure of the frequency of cells that have gone through more than three divisions (positive proliferation, CFSE^low^) (Figure [1C](#F1){ref-type="fig"} and D)\[[@B28]-[@B30]\]. The final PI was determined by calculating the ratio of the average PI for mitogen- or antigen-stimulated cells divided by the average PI of unstimulated cells (Figure [1](#F1){ref-type="fig"}). The highly expressed surface markers on the T, NK and NKT cell subsets that were activated by antigenic stimulation (R1 + R2) were considered in the off-line software analysis (*e.g*., Figure [1A](#F1){ref-type="fig"} and B, and Figure [2](#F2){ref-type="fig"}). The cell culture supernatants were assayed to quantify IL-6, IL-8, IL-10, IFNγ and TNFα using commercially available Standard ELISA Development kits (Peprotech, United States). Human cytokine IL-17/17A was quantified with the commercially available Mini ELISA Development kit (Peprotech, United States).

![Flow cytometry analysis of proliferating mononuclear cells in antigenic stimulation. Mononuclear cell populations were gated using forward (FSC) and side (SSC) scatter, and the dot plot identifies the total cells (R1 + R2), resting cells (R1) and blasts (R2). Peripheral blood mononuclear cells, either unstimulated (A and C) or stimulated with antigens (PHA, LPS or HAV Ag) (B and D), were labeled with CFSE. The histograms show the proportion of total (CFSE^low^ + CFSE^high^), resting (CFSE^high^) and proliferating cells (CFSE^low^) observed using the Cyan flow cytometer and analyzed using the off-line software Summit version 6.0. CFSE: Carboxyfluorescein succinimidyl ester; PHA: Phytohemagglutinin; LPS: Lipopolysaccharide.](WJH-8-1370-g001){#F1}

![Hepatitis A virus Ag-activated CD4^+^ T cells in acute liver disease caused by hepatitis A virus. The data from three subjects selected from our study groups were used to represent the gating strategy to select CD29^+^CD44^+^ and CD25^+^FoxP3^+^ on CD4^+^ cells (CD3^+^CD8^-^). Representative contour plots of the frequency of migratory T helper cells (%) in HAV Ag-activated mononuclear cells from healthy subjects (A), patients with acute hepatitis A (B), patients with acute liver failure with HAV infection (C) and in HAV Ag-activated regulatory T cells from healthy subjects (D), patients with acute hepatitis (E), and patients with acute liver failure (F). HAV: Hepatitis A virus.](WJH-8-1370-g002){#F2}

Statistical analysis
--------------------

The data are expressed as the mean ± standard deviation (SD) at a 95%CI. The distribution of the data in the groups was initially evaluated by the Kolmogorov-Smirnov test. The correlations were evaluated using the Spearman rank correlation test (R project for Statistical Computing (<http://www.r-project.org/>). The differences between self-limited AH, ALF, and healthy subjects were evaluated by intergroup comparisons using the Kruskal-Wallis test. If a significant difference was found, a pair of variables in the three groups was assessed with the Mann-Whitney *U*-test. For the plasma samples, receiver operating characteristic (ROC) curve analysis was used to compare the predictive strength of markers with chance. The area under the curve was used as a measure of the ability of the test to distinguish between the two groups. The software GraphPad Prism 5 for Windows, version 5.01 (San Diego, CA, United States), was used to perform statistical ROC curve analysis. Multivariate logistic regression was applied to select the independent predictors in plasma samples associated with ALF based on cut-off points (90% specificity and with the highest likelihood ratio value) obtained from ROC curve analysis. In the initial logistic model, all variables were tested for predictive strength. The variables showing statistically significant differences were kept in the final model. The logistic regression analyses were performed using SPSS software version 17.0 for Windows (SPSS Inc., Chicago, IL, United States). The significance for all statistical analyses was defined as *P* \< 0.05.

RESULTS
=======

Characterization of the AH and ALF patients
-------------------------------------------

Non-viral ALF cases were caused by α-methyldopa (1 patient), rifampicin (1), and cryptogenic disease (3). The self-limited AH were caused by NSAIDs (2) and cryptogenic disease (6). HAV infection was the viral etiology found in self-limited AH (38) and ALF (11). The mean ± SD of viral load for the HAV was 1.4 × 10^6^ ± 8.6 × 10^5^ HAV-RNA/mL in plasma samples from ALF patients and 3.6 × 10^3^ ± 1.8 × 10^3^ HAV-RNA/mL in samples from AH self-limited patients (AH).

The time of blood collection in self-limited AH was 1-4 wk in the HAV-AH group and 2-6 wk in the non-viral AH group. In the ALF patient group it was 1-3 wk for HAV-ALF and non-viral ALF. Three patients with acute HAV infection, INR \< 1.5 and no coma grade (HE \< I) had their samples collected before the evolution to liver failure. They progressed to death before transplant, according to medical records, so they were included in the ALF group. Table [1](#T1){ref-type="table"} shows more information about the study population, including age, gender, coma grade, coagulopathy, liver enzymes, total bilirubin, and outcome.

###### 

Clinical characteristics of the studied population *n* (%)

                            **Acute liver failure (*n* = 16)**   **Acute hepatitis (*n* = 46)**   **Healthy control (*n* = 22)**
  ------------------------- ------------------------------------ -------------------------------- --------------------------------
  Age (yr)                                                                                        
  Mean ± SD                 24.88 ± 21.52                        21.21 ± 10.32                    24.64 ± 8.79
  25%, 75%                  9.25, 49                             9.1, 29.75                       15.2, 47
  Gender                                                                                          
  Male                      6 (37.50)                            25 (54.34)                       9 (40.9)
  Diagnosis                                                                                       
  Hepatitis A               11 (68.75)                           38 (82.60)                       0
  Drug toxicity             2 (12.50)                            2 (4.34)                         0
  Indeterminate             3 (18.75)                            6 (13.04)                        0
  Liver enzymes                                                                                   
  AST (UI/L)                1095.5 ± 1460                        344.5 ± 444.9                    21.68 ± 4.87
  ALT (UI/L)                806.12 ± 639.11                      517.90 ± 884.30                  14.36 ± 4.50
  Total bilirubin (mg/dL)   21.47 ± 10.48                        10.01 ± 6.88                     0.85 ± 0.09
  Coma grade                                                                                      
  0-I                       3 (18.75)                            0                                0
  II-IV                     13 (81.25)                           0                                0
  Coagulopathy                                                                                    
  INR (mean ± SD)           4.88 ± 0.99                          1.16 ± 0.04                      0.98 ± 0.06
  Outcome                                                                                         
  Survived                  6 (46.15)                            46 (100.00)                      22 (100)
  Died                      10 (53.84)                           0                                0

INR: International normalized ratio; SD: Standard deviation; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.

Elevated plasma cytokines and mtDNA are seen in AH and ALF patients compared to healthy controls
------------------------------------------------------------------------------------------------

The intensity of the inflammatory status was not associated with etiology (*P* \> 0.05). Table [2](#T2){ref-type="table"} compares the systemic inflammatory parameters between clinical conditions. The cytokines IL-6, IL-8, IL-10 and IFNγ were significantly raised in the AH and ALF patients compared to the healthy subjects. TNFα was also elevated in the ALF patients compared to the healthy subjects (Table [2](#T2){ref-type="table"}). Similarly, total mtDNA was significantly higher in both the AH and ALF groups than in the healthy controls. ALF patients showed a significant elevation in IL-6, IL-10, IFNγ and TNFα as well as high levels of mtDNA compared to the AH patients (Table [2](#T2){ref-type="table"}).

###### 

Systemic inflammatory products in the plasma samples from patients with acute hepatitis or acute liver failure and healthy subjects

  **Plasma variables**                           **HC (*n* = 22)**                                            **AH (*n* = 49)**             **ALF (*n* = 13)**              **HC *vs* AH[a](#T2FN3){ref-type="table-fn"}**   **HC *vs* ALF**   **AH *vs* ALF**
  ---------------------------------------------- ------------------------------------------------------------ ----------------------------- ------------------------------- ------------------------------------------------ ----------------- -----------------
  IL-6 (pg/mL)                                   15.07 ± 25.92 (3.58-26.57)[1](#T2FN1){ref-type="table-fn"}   68.93 ± 109.7 (38.39-99.46)   509.30 ± 678.70 (147.6-870.9)   0.0009                                           \< 0.0001         \< 0.0001
  IL-8 (pg/mL)[2](#T2FN2){ref-type="table-fn"}   ND                                                           10.50 ± 20.05 (4.92-16.09)    144.70 ± 437.6 (-88.45-377.9)   \< 0.001                                         \< 0.0001         ns
  IL-10 (pg/mL)                                  1.81 ± 5.58 (-0.66-4.28)                                     17.28 ± 51.97 (2.81-31.75)    249.60 ± 379.60 (47.35-451.9)   0.0006                                           \< 0.0001         \< 0.0001
  IFNγ (pg/mL)                                   4.80 ± 18.00 (-3.18-12.79)                                   113.0 ± 265.33 (39.1-186.8)   229.70 ± 342.20 (47.37-412.1)   0.0075                                           \< 0.0001         0.0016
  TNFα (pg/mL)                                   1.08 ± 2.38 (0.02-2.13)                                      27.25 ± 64.05 (9.42-45.08)    179.40 ± 161.40 (93.42-265.4)   ns                                               \< 0.0001         \< 0.0001
  mtDNA (ng/100 μL plasma)                       81.79 ± 121.6 (27.88-135.7)                                  159.6 ± 202.2 (64.99-254.3)   4228.00 ± 4286.0 (1944-6512)    0.0131                                           \< 0.0001         0.0008

Mean ± standard deviation (95%CI);

IL-8 levels in the plasma samples were evaluated only by the Kruskal-Wallis test.

*P* \< 0.05. The differences between the acute liver failure patients, the self-limited acute hepatitis patients and the healthy controls were evaluated by intergroup comparisons using the Mann-Whitney *U*-test. IL: Interleukin; IFNγ: Interferon gamma; TNFα: Tumor necrosis factor alpha; mtDNA: Total mitochondrial DNA; ND: Not detectable; ns: Not significant; HC: Healthy control; AH: Acute hepatitis (viral plus non-viral etiologies); ALF: Acute liver failure (viral plus non-viral etiologies).

Elevated plasma cytokines and mtDNA are positively correlated with the degree of liver damage, as represented by the presence of HE or coagulopathy
---------------------------------------------------------------------------------------------------------------------------------------------------

When we evaluated the correlations between INR and HE and the plasma cytokine and mtDNA levels, the HE grade showed significant positive correlations with IL-6 (*P* \< 0.0001), IL-10 (*P* \< 0.0001), TNFα (*P* = 0.0001), and IL-8 (*P* = 0.0034) (Supplementary Figure [1A](#F1){ref-type="fig"}, C, E and G). The elevated INR values showed significant positive correlations with IL-6 (*P* \< 0.0001), IL-10 (*P* = 0.0002), TNFα (*P* = 0.0004) and IFNγ (*P* = 0.0057) (Supplementary Figure [1B](#F1){ref-type="fig"}, D, F and H). A positive correlation was observed between mtDNA and HE (*P* = 0.0002; Supplementary Figure [1I](#F1){ref-type="fig"}) as well as INR (*P* = 0.0043; Supplementary Figure [1J](#F1){ref-type="fig"}).

Elevated cytokines and mtDNA are correlated with outcome in ALF
---------------------------------------------------------------

To determine whether the plasma concentrations of the inflammatory or anti-inflammatory cytokines could be used as indicators of liver dysfunction, we used ROC curve analysis, which showed that IL-6 (*P* \< 0.0001), IL-10 (*P* \< 0.0001), TNFα (*P* \< 0.0001), and IFNγ (*P* \< 0.00104) had the highest diagnostic accuracy for ALF. When we evaluated hepatocyte damage, the ROC curve showed that mtDNA (*P* = 0.0046) had the highest diagnostic accuracy for ALF.

Among the cytokines, elevated IL-10 was the best indicator of ALF (*P* = 0.028). Although the IL-6, IL-8, IFNγ and TNFα levels had a positive correlation with hepatic encephalopathy, the association with ALF was not significant (Table [3](#T3){ref-type="table"}). Elevated mtDNA (*P* \< 0.0001) was associated with ALF diagnosis.

###### 

Potential clinical and inflammatory parameters as indicators of acute liver failure syndrome and death

                                                     **Cut-off**   **Adjusted OR**   **95%CI**       ***P* value**
  -------------------------------------------------- ------------- ----------------- --------------- ---------------
  Plasma variables[1](#T3FN1){ref-type="table-fn"}                                                   
  IL-6 (pg/mL)                                       \> 197.6      1.36              0.04-40.27      0.856
  IL-10 (pg/mL)                                      \> 55.77      18.86             1.38-257.94     0.028
  TNFα (pg/mL)                                       \> 122.6      4.42              0.185-105.93    0.359
  mtDNA (ng/100 μL plasma)                           \> 174        320.54            14.42-7123.33   0.000
  Plasma variables[2](#T3FN2){ref-type="table-fn"}                                                   
  IL-6 (pg/mL)                                       \> 473.2      2.27              0.19-26.92      0.515
  IL-8 (pg/mL)                                       \> 66.30      10.42             1.54-70.45      0.016
  IL-10 (pg/mL)                                      \> 95.71      8.01              1.26-50.97      0.027
  TNFα (pg/mL)                                       \> 313.7      0.27              0.03-2.17       0.220
  mtDNA (ng/100 μL plasma)                           \> 405.3      12.11             2.57-57.07      0.002
  INR                                                \> 2.12       29.88             5.44-164.19     0.000

Multivariate analysis from clinical and inflammatory parameters associated with ALF;

Multivariate analysis from clinical and inflammatory parameters associated with death. OR: Odds ratio; IL: Interleukin; IFNγ: Interferon gamma; TNFα: Tumor necrosis factor alpha; mtDNA: Total mitochondrial DNA; ALF: Acute liver failure; INR: International normalized ratio.

Subsequently, the indicators that were associated with death were investigated in all 62 acute liver disease patients: 52 survived (AH and ALF patients) and 10 died (ALF patients). Figure [3](#F3){ref-type="fig"} shows that the mtDNA (*P* \< 0.01) and all investigated cytokines were significantly elevated in the non-surviving patients (*P* \< 0.01). The ROC curve analysis showed that elevated INR, IL-6, IL-8, IL-10, TNFα, IFNγ and mtDNA in the plasma samples were able to discriminate survivors from non-survivors with a sensitivity and specificity above 70%. The high plasma levels of mtDNA, IL-8, IL-10 and INR were considered predictive factors for poor outcome (death) in patients with acute liver disease (Table [3](#T3){ref-type="table"}). Despite the high levels of IL-6, and TNFα, these factors did not predict death (Figure [3](#F3){ref-type="fig"} and Table [3](#T3){ref-type="table"}).

![Differences in inflammatory cytokines (interleukin 6, 8 and 10, interferon gamma, and tumor necrosis factor α) and hepatocyte damage (mitochondrial DNA) parameters between the surviving and non-surviving patients. ^b^*P* \< 0.01; ^d^*P* \< 0.001. IL-6: Interleukin 6; IFNγ: Interferon gamma; TNFα: Tumor necrosis factor alpha; mtDNA: Mitochondrial DNA.](WJH-8-1370-g003){#F3}

***Changes in the frequency of mononuclear cell phenotypes and cytokine secretion after the clonal proliferation assay are associated with virus (HAV)- induced AH and ALF syndrome***

The panel of phenotypic analyses for PBMC clonal proliferation was composed of activated and migratory T helper cells (CD4^+^CD29^+^CD44^+^), activated and migratory cytotoxic T cells (CD8^+^CD29^+^CD44^+^), activated NK cells \[CD3^-^CD56^low^CD16^+^ (NK^dim^), CD3^-^CD56^+^CD16^-^ (NK^bright^)\], and NKT cells (CD3^+^CD16^+^CD56^+^). Mitogens (PHA and LPS) and virus particles (HAV Ag) were used for non-specific and specific PBMC proliferation, respectively. The mitogen stimulation showed a reduced frequency (anergic behavior) in all investigated phenotypes from HAV-induced hepatitis (ALF and AH patients) (Table [4](#T4){ref-type="table"}). The same patients, when stimulated with HAV Ag, exhibited positive proliferation of the regulatory (CD4^+^CD25^+^FoxP3^+^), NKT (CD3^+^CD16^+^CD56^+^), and NK^bright^ (CD3^-^CD56^+^CD16^-^) phenotypes, and only the helper phenotype (CD4^+^CD29^+^CD44^+^) frequency was reduced in HAV-induced ALF patients (Figure [2](#F2){ref-type="fig"}). In general, the PBMCs from HAV-induced AH showed a tendency toward negative proliferation after mitogen stimulation in all analyzed phenotypes. A significant decrease was detected in in the T helper and NKT cells (AH *vs* HC) (Table [4](#T4){ref-type="table"}). The PBMCs showed a significant positive proliferation of the T helper, cytotoxic (CD8^+^CD29^+^CD44^+^), and NKT cells with HAV-specific stimulation.

###### 

Variables from the mitogen-stimulated peripheral blood mononuclear cell phenotypes from patients with acute hepatitis A infection and healthy subjects

  **Phenotypes/cytokines (PHA/LPS)**   **HC (*n* = 10)**   **AH (*n* = 8)**   **ALF (*n* = 8)**   **HC *vs* AH**   **HC *vs* ALF**   **AH *vs* ALF**
  ------------------------------------ ------------------- ------------------ ------------------- ---------------- ----------------- -----------------
  PI of CD3^+^                         133.1 ± 71.12       44.4 ± 25.83       17.48 ± 5.94        0.0155           0.0021            0.0426
                                       (95.19-171.0)       (22.80-65.99)      (11.24-23.72)                                          
  CD4^+^CD25^+^FoxP3^+^ (%)            17.23 ± 9.74        17.08 ± 5.37       5.99 ± 2.80         ns               0.0009            0.0003
                                       (12.03-22.42)       (12.59-21.57)      (3.65-8.33)                                            
  CD4^+^CD29^+^CD44^+^ (%)             38.63 ± 18.37       20.75 ± 7.82       10.22 ± 4.74        0.0062           \< 0.0001         0.0047
                                       (28.84-48.42)       (14.21-27.29)      (6.25-14.18)                                           
  CD8^+^CD29^+^CD44^+^ (%)             39.76 ± 19.91       37.56 ± 25.01      9.03 ± 4.59         ns               0.0002            0.0104
                                       (29.15-50.36)       (16.74-58.57)      (5.18-12.88)                                           
  CD3^-^CD56^+^CD16^-^ (%)             8.31 ± 6.75         4.19 ± 2.28        0.50 ± 0.37         ns               0.0006            0.0009
                                       (2.07-14.56)        (2.08-6.30)        (0.15-0.84)                                            
  CD3^-^CD56^low^CD16^+^ (%)           12.70 ± 8.93        8.52 ± 5.68        1.11 ± 0.66         ns               0.0012            0.0018
                                       (4.44-20.96)        (3.26-13.78)       (0.50-1.72)                                            
  CD3^+^CD56^+^CD16^+^ (%)             13.66 ± 3.54        7.20 ± 5.28        1.83 ± 1.06         0.0117           \< 0.0001         0.0070
                                       (11.77-15.55)       (2.79-11.63)       (0.94-2.72)                                            
  IL-6 (pg/mL)                         2625.33 ± 3320      565.7 ± 313.3      156.8 ± 173.9       0.0155           \< 0.0001         0.0070
                                       (856.5-4394)        (303.8-827.6)      (11.40-302.2)                                          
  TNFα (pg/mL)                         1675.20 ± 623.4     1405.0 ± 324.3     145.3 ± 107.9       ns               \< 0.0001         0.0002
                                       (1343-2007)         (1134-1676)        (55.09-235.5)                                          
  IL-10 (pg/mL)                        528.86 ± 755.1      269.5 ± 145.8      188.4 ± 267.1       ns               0.0454            ns
                                       (126.5-931.2)       (147.6-391.5)      (-16.88-393.7)                                         
  IFNγ (pg/mL)                         3379.1 ± 1869       2467.0 ± 2787      1249.0 ± 2067       ns               0.0205            ns
                                       (2383-4375)         (137.1-4798)       (-479.2-2977)                                          
  IL-8 (pg/mL)                         273.9 ± 116.3       274.2 ± 148.5      151.0 ± 156.4       ns               0.0205            0.0379
                                       (211.9-335.9)       (150.0-398.3)      (20.21-281.8)                                          
  IL-17 (pg/mL)                        73.81 ± 107.0       31.55 ± 35.58      4.16 ± 3.20         ns               0.0029            0.0116
                                       (16.81-130.8)       (1.80-61.30)       (1.49-6.84)                                            

The differences between the hepatitis A-induced acute liver failure (ALF) patients, the self-limited acute hepatitis A (AH) patients, and the healthy control (HC) subjects were evaluated by intergroup comparisons using the Mann-Whitney *U*-test. The significance cutoff for all statistical analyses was defined as *P* \< 0.05. IL: Interleukin; IFNγ: Interferon gamma; TNFα: Tumor necrosis factor alpha; ns: Not significant; PI: Proliferation index.

The secreted cytokines, IL-6, TNFα, IL-8 and IL-17, were reduced in the supernatant of HAV-induced hepatitis PBMCs from ALF patients compared to AH patients during mitogen stimulation. Additionally, IL-10 and IFNγ were reduced in ALF patients *vs* the HC subjects. In patients with AH A, we observed a significant reduction in IL-6 secretion and a general tendency toward a reduced secretion of all cytokines, but there were no significant differences (Table [4](#T4){ref-type="table"}).

The analysis of the secreted cytokines after HAV Ag stimulation of PBMCs from HAV-induced hepatitis patients showed reduced levels of TNFα and IL-17 when comparing the ALF and AH patients. Reduced levels of secreted TNFα were also observed in the ALF patients compared to the HC subjects. Additionally, we observed elevated levels of secreted IL-10 and IFNγ. The ALF patients presented elevated levels of secreted IL-8 compared to the HC subjects. The levels of secreted IL-10, IFNγ, IL-8 and IL-17 were elevated in cultures from the AH patients (Table [5](#T5){ref-type="table"}).

###### 

Variables from hepatitis A virus Ag-stimulated peripheral blood mononuclear cell phenotypes from patients with acute hepatitis A infection and healthy subjects

  **Phenotypes/cytokines (HAVAg)**   **HC (*n* = 10)**   **AH (*n* = 8)**   **ALF (*n* = 8)**   **HC *vs* AH**   **HC *vs* ALF**   **AH *vs* ALF**
  ---------------------------------- ------------------- ------------------ ------------------- ---------------- ----------------- -----------------
  PI of CD3^+^                       1.09 ± 0.85         3.15 ± 1.92        3.34 ± 2.29         0.0053           0.0044            ns
                                     (0.64-1.55)         (1.54-4.76)        (1.42-5.25)                                            
  CD4^+^CD25^+^FoxP3^+^ (%)          0.85 ± 0.96         1.0 ± 0.97         3.19 ± 1.49         ns               0.0011            0.0070
                                     (0.34-1.37)         (0.18-1.81)        (1.95-4.44)                                            
  CD4^+^CD29^+^CD44^+^ (%)           11.99 ± 6.43        27.93 ± 8.16       5.46 ± 5.92         0.0008           0.0077            0.0006
                                     (8.55-15.42)        (21.1-34.76)       (0.50-10.42)                                           
  CD8^+^CD29^+^CD44^+^ (%)           12.65 ± 4.31        30.13 ± 6.74       36.05 ± 10.59       0.0001           0.0001            ns
                                     (10.35-14.95)       (24.49-35.77)      (27.19-44.90)                                          
  CD3^-^CD56^+^CD16^-^ (%)           0.19 ± 0.20         0.30 ± 0.19        1.33 ± 0.85         ns               0.0009            0.0005
                                     (0.05-0.34)         (0.13-0.46)        (0.62-2.04)                                            
  CD3^-^CD56^low^CD16^+^ (%)         4.28 ± 2.22         10.09 ± 8.94       14.24 ± 11.81       ns               ns                ns
                                     (2.70-5.87)         (2.61-17.5)        (4.36-24.12)                                           
  CD3^+^CD56^+^CD16^+^ (%)           1.67 ± 2.71         4.25 ± 4.06        15.06 ± 7.74        0.0110           0.0003            0.0019
                                     (0.22-3.12)         (0.85-7.65)        (8.58-21.53)                                           
  IL-6 (pg/mL)                       50.49 ± 76.14       76.41 ± 93.18      139.7 ± 165.9       ns               ns                ns
                                     (9.92-91.06)        (-1.46-154.3)      (0.98-278.4)                                           
  TNFα (pg/mL)                       92.49 ± 133.4       23.96 ± 28.92      1.63 ± 1.01         ns               0.0089            0.0098
                                     (21.42-163.6)       (-0.21-48.14)      (0.78-2.48)                                            
  IL-10 (pg/mL)                      10.39 ± 13.97       52.78 ± 62.06      164.3 ± 75.56       0.0297           0.0001            0.0148
                                     (2.94-17.84)        (0.89-104.7)       (101.1-227.5)                                          
  IFNγ (pg/mL)                       0.88 ± 1.08         106.6 ± 183.9      1095 ± 1962         0.0035           0.0001            0.0499
                                     (0.30-1.46)         (-47.14-260.4)     (-546-2735)                                            
  IL-8 (pg/mL)                       88.64 ± 45.40       148.9 ± 54.77      150.2 ± 72.19       0.0131           0.0110            ns
                                     (64.44-112.8)       (103.1-194.7)      (89.84-210.5)                                          
  IL-17 (pg/mL)                      3.36 ± 3.75         32.61 ± 38.30      7.58 ± 5.43         0.0008           ns                0.0499
                                     (1.36-5.36)         (0.59-64.64)       (3.05-12.13)                                           

The differences between the hepatitis A-induced acute liver failure (ALF) patients, the self-limited acute hepatitis A (AH) patients and the healthy control (HC) subjects were evaluated by intergroup comparisons using the Mann-Whitney *U*-test. The significance cutoff for all statistical analyses was defined as *P* \< 0.05. IL: Interleukin; IFNγ: Interferon gamma; TNFα: Tumor necrosis factor alpha; ns: Not significant; PI: Proliferation index.

Changes in the frequency of mononuclear cell phenotypes and cytokine secretion after the clonal proliferation assay in non-viral-induced AH and ALF
---------------------------------------------------------------------------------------------------------------------------------------------------

We observed a tendency toward positive proliferation for the migratory T helper (CD4^+^CD29^+^CD44^+^) and cytotoxic T (CD8^+^CD29^+^CD44^+^) cells for IL-6 and IL-17 release in the ALF patients compared to the AH patients. Significant elevations of NK^dim^ (CD3^-^CD56^low^CD16^+^) and NK^bright^ (CD3^-^CD56^+^CD16^-^) cell frequencies were associated with high levels of TNFα in the non-viral ALF patients compared to the AH patients and the HC subjects. The IL-8 levels were also significantly elevated in the ALF patients compared to the HC subjects (Table [5](#T5){ref-type="table"}). In general, the comparison between the PBMCs from non-viral AH patients and the HC subjects showed a tendency toward a negative proliferation of all phenotypes investigated and the secreted cytokines IL-6, IL-10, IFNγ and IL-17 (Table [6](#T6){ref-type="table"}).

###### 

Variables from mitogen-stimulated peripheral blood mononuclear cells from non-viral acute hepatitis patients and healthy control subjects

  **Phenotypes/cytokines (PHA/LPS)**   **HC (*n* = 10)**   **AH (*n* = 8)**   **ALF (*n* = 5)**   **HC *vs* AH**   **HC *vs* ALF**   **AH *vs* ALF**
  ------------------------------------ ------------------- ------------------ ------------------- ---------------- ----------------- -----------------
  PI of CD3^+^                         133.1 ± 71.12       173.3 ± 91.84      268.4 ± 101.6       ns               ns                ns
                                       (95.19-171.0)       (96.51-250.1)      (142.3-394.5)                                          
  CD4^+^CD25^+^FoxP3^+^ (%)            17.23 ± 9.74        15.82 ± 8.13       6.84 ± 5.12         ns               ns                ns
                                       (12.03-22.42)       (9.02-22.62)       (0.48-13.2)                                            
  CD4^+^CD29^+^CD44^+^ (%)             38.63 ± 18.37       21.84 ± 7.50       36.67 ± 14.54       ns               ns                ns
                                       (28.84-48.42)       (15.56-28.11)      (18.61-54.73)                                          
  CD8^+^CD29^+^CD44^+^(%)              39.76 ± 19.91       22.26 ± 11.16      29.59 ± 15.21       ns               ns                ns
                                       (29.15-50.36)       (12.92-31.59)      (10.71-48.47)                                          
  CD3^-^CD56^+^CD16^-^ (%)             8.31 ± 6.75         6.33 ± 4.13        17.22 ± 4.94        ns               0.0289            0.0030
                                       (2.07-14.56)        (2.88-9.79)        (13.09-21.35)                                          
  CD3^-^CD56^low^CD16^+^ (%)           12.70 ± 8.93        11.38 ± 4.67       27.66 ± 3.49        ns               0.0061            0.007
                                       (4.44-20.96)        (7.05-15.71)       (22.11-33.21)                                          
  CD3^+^CD56^+^CD16^+^ (%)             13.66 ± 3.54        11.63 ± 3.01       8.52 ± 4.97         ns               ns                ns
                                       (11.77-15.55)       (9.11-14.15)       (2.35-14.70)                                           
  IL-6 (pg/mL)                         2625.33 ± 3320      966 ± 622.6        1309 ± 851.6        ns               ns                ns
                                       (856.5-4394)        (445.5-1486.0)     (251.60-2366)                                          
  TNFα (pg/mL)                         1675.20 ± 623.4     1497 ± 219.8       3217 ± 991.5        ns               0.0044            0.0016
                                       (1343-2007)         (1313-1681)        (1986-4448)                                            
  IL-10 (pg/mL)                        528.86 ± 755.1      217.1 ± 159.1      152.1 ± 126.4       ns               ns                ns
                                       (126.5-931.2)       (84.12-350.2)      (-4.89-309.0)                                          
  IFNγ (pg/mL)                         3379.1 ± 1869       2257 ± 2872        1378 ± 2533         ns               ns                ns
                                       (2383-4375)         (-143.3-4658)      (-1767-4524)                                           
  IL-8 (pg/mL)                         273.9 ± 116.3       293.9 ± 120.2      733.1 ± 404.8       ns               0.0267            ns
                                       (211.9-335.9)       (193.4-394.4)      (230.4-1236)                                           
  IL-17 (pg/mL)                        73.81 ± 107.0       36.31 ± 34.62      62.73 ± 5.78        ns               ns                ns
                                       (16.81-130.8)       (7.36-65.25)       (55.55-69.91)                                          

The differences between the non-viral acute liver failure (ALF) patients, the self-limited acute hepatitis (AH) patients, and the healthy control (HC) subjects were evaluated by intergroup comparisons using the Mann-Whitney *U*-test. The significance cutoff for all statistical analyses was defined as *P* \< 0.05. IL: Interleukin; IFNγ: Interferon gamma; TNFα: Tumor necrosis factor alpha; PI: Proliferation index; HC: Healthy control; ns: Not significant.

Evidence of effects on the TReg and migratory T helper cells obtained from viral and non-viral AH and ALF patients
------------------------------------------------------------------------------------------------------------------

To understand the influence of the TReg in AH and ALF, we evaluated the balance between the frequency of TReg with the innate and adaptive immune cells studied. Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"} reveal the change in the frequencies of TReg (CD4^+^CD25^+^FoxP3^+^) and migratory T helper frequencies (CD4^+^CD29^+^CD44^+^) in viral ALF after HAV stimulation and in non-viral ALF after mitogen stimulation. Figure [4A](#F4){ref-type="fig"} shows an elevated TReg-to-Thelper ratio in the HAV-induced ALF patients after HAV stimulation compared to the AH patients and the HC subjects. No changes in the ratios between the TReg and the other phenotypes were observed. After mitogen stimulation, the imbalance between the TReg-to-T helper ratio was significantly reduced in the non-viral ALF patients compared to the AH patients (Figure [4B](#F4){ref-type="fig"}). For the other investigated phenotypes, the alterations in this ratio were not significant.

![Imbalance between peripheral CD4^+^ regulatory T cells and migratory T helper cells in viral and non-viral acute hepatitis cases. A: Comparison of the ratio of CD4^+^ TReg-to-Thelper in HAV-induced acute liver disease (ALF and AH) and healthy controls (HC); B: Comparison of the ratio of CD4^+^ TReg-to-Thelper cells in non-viral-induced acute liver disease (ALF and AH). ^a^*P* \< 0.05, ^b^*P* \< 0.01; ^d^*P* \< 0.001. HAV: Hepatitis A virus; AH: Acute hepatitis; ALF: Acute liver failure.](WJH-8-1370-g004){#F4}

DISCUSSION
==========

Acute viral hepatitis was represented by hepatitis A cases in our study. There are a large number of outbreaks of hepatitis A in Brazil; HAV infection is the major etiology of AH and ALF\[[@B17],[@B31],[@B32]\]. Here, we introduced plasma mtDNA level as a new predictor for HAV-induced ALF syndrome. In our opinion, the gross elevation of mtDNA in the ALF patients resulted from massive liver necrosis, as expected. mtDNA, inflammatory and anti-inflammatory cytokines and effector cells are involved in drug-induced liver failure in murine models and in patients\[[@B5],[@B8],[@B33]\].

Increased levels of cytokines and chemokines have been observed in all ALF and non-surviving patients, as described by other authors investigating both drug- and viral-induced ALF\[[@B5],[@B34]-[@B36]\]. In our study, the high levels of IL-8 and IL-10 were predictive markers of death in acute liver disease.

Additionally, the imbalance between IL-10 and IL-12 levels has been noted in HBV-induced ALF\[[@B37]\], indicating an ineffective attempt to activate the anti-inflammatory pathway\[[@B38]-[@B40]\]. The elevated plasma levels of IL-8 that were detected in all cases of ALF are also described in patients with drug-induced ALF and are correlated with granulocyte migration into the liver parenchyma\[[@B5],[@B41]\]. The elevated levels of circulating IL-6 and TNFα, also described by others\[[@B42],[@B43]\], have been related to attempts at liver regeneration\[[@B44],[@B45]\] and liver injury\[[@B46]\], respectively. Therapeutic approaches targeting the clearance of inflammatory/toxic products (plasmapheresis, hemodiafiltration, and bioartificial livers) from the liver or anti-cytokine therapy are currently being considered\[[@B42],[@B47]-[@B49]\] despite contradictory clinical results\[[@B50],[@B51]\].

Even though the profile of monocytes was not explored here, several studies showed the important role of these cells in association with their activation, migration to the liver, and differentiation into hepatic macrophages induced by grow-factor β and IL-10 in humans\[[@B52],[@B53]\] and experimental animal models\[[@B54]\]. Production of the inflammatory cytokines TNF, IL1-β, IL-6, IL-8 and MCP-1 by hepatic macrophages has been associated with cytokine storm in liver injury\[[@B52],[@B53]\]. These findings could explain the biological relevance of high levels of circulating IL-6, IL-8 and IL-10 in ALF patients with the worst outcomes, which were produced by activated monocytes/macrophages, by antigen presentation, and by T cell proliferation.

When we evaluated the linear correlation between coagulopathy/encephalopathy and the plasma variables studied, we observed that the INR and HE scores increased in ALF cases. mtDNA, IL-6, IL-10, IFNγ, TNFα and IL-8 were also significantly elevated and were positively correlated with the elevated INR and/or HE scores observed in severe liver disease. Thus, this study also showed that elevated mtDNA and IL-10 are positively associated with the risk of ALF and mortality. Other authors described IL-10 as an important immunosuppressive cytokine that is released by TReg and is strongly expressed in HBV-induced acute-on-chronic liver failure\[[@B38],[@B55],[@B56]\].

Indeed, the most puzzling fact revealed here was the anergic behavior of the PBMCs from HAV-induced AH and ALF after *in vitro* mitotic stimulation. This fact may be explained by PBMC clonal exhaustion\[[@B57]-[@B59]\] or may suggest that the- TReg influence HAV Ag-primed PBMCs *in vivo* during AH and ALF syndrome\[[@B23]\]. In addition, when the TReg cells have been previously primed by a specific antigen (*e.g*., viral antigen), they may develop a non-specific suppressor activity, as described by others\[[@B60]\].

Here, the impairment of the PBMC response was associated with liver dysfunction in patients with AH A. The high TReg cell frequencies in HAV-induced ALF and the increase in IL-10 after HAV Ag stimulation were consistent with the reduced frequency found for the Th17 migratory phenotype (CD4^+^CD29^+^CD44^+^ and IL-17 secretion) and the modulation of the T lymphocyte (CD3^+^) and cytotoxic T cell (CD8^+^CD29^+^CD44^+^) phenotypes.

Our results suggest that the negative regulation of the TReg cells attempts to control liver inflammation and disease progression by reducing the Th17 migration to the liver tissue in patients with HAV-induced ALF. A similar profile of antigen-specific and unspecific stimulation was observed in patients with HEV-induced AH and ALF\[[@B59]\] and in chronic hepatitis B infection after anti-CD3/CD28 (unspecific) stimulation\[[@B56]\]. Our results did not confirm the TReg influence in non-viral ALF patients, which corroborates other results\[[@B61]-[@B63]\]. The expansion of T helper cells (Th17) and the suppression TReg cell production are involved in the mechanisms of liver damage in drug-induced liver disease\[[@B61],[@B63]\].

In HAV-AH, T helper cell proliferation was increased after HAV Ag stimulation and was reduced after mitogen stimulation. The scarce literature available describes defects in cell signaling in CD4^+^ T cells that are secondary to ALF\[[@B59]\]. Other authors reported that an increase in TReg cells and a decrease in Th17 cells are associated with the survival of HBV-related acute-on-chronic liver failure patients\[[@B56]\], although contradictory opinions have been reported\[[@B38],[@B64]\]. In our study, a similar profile was exhibited by migratory cytotoxic T cells (CD8^+^CD29^+^CD44^+^) for both antigens (viral and mitogen) in HAV-induced AH and ALF. Impaired proliferation was also demonstrated with HEV Ag (pORF3), which was dependent on ERK activation (a member of mitogen-activated protein kinase) and involved in cell proliferation through the TCR/CD3 complex\[[@B65]\].

A linear reduction of NK^bright^, NK^dim^ and NKT cell reactivity occurred after mitogen stimulation in patients with HAV-induced AH and ALF, which was reversed by HAV Ag-stimulation. The loss of NK^dim^ reactivity in our ALF patients corroborated the suppressor function of the TReg cells, as described above, which appears to modulate the NK-mediated liver injury. A marked elevation in the frequency of NK^bright^ and NKT cells in patients with HAV-induced ALF reinforces the importance of these cells in liver injury\[[@B19],[@B66]-[@B69]\].

The significant reduction in the secreted TNFα levels following the HAV Ag-stimulation of patients with HAV-induced AH and ALF shown here was also observed by other authors in HEV-induced AH and ALF\[[@B59]\]. However, TNFα, IL-17 and T helper cell reactivity are positively correlated with the progression to chronic liver disease and acute-on-chronic liver failure in hepatitis B infection\[[@B39],[@B64]\]. In addition, Zhou et al\[[@B70]\] (2012) observed a reduced frequency of the CD4^+^IL-2^+^IFNγ^+^TNF^+^ population after resolution of hepatitis A, suggesting an increased risk of hepatitis relapse. We observed that the frequency of T cells was not reduced in mitogen stimulated non-viral-induced AH and ALF. The NK^bright^ and NK^dim^ cells with TNFα and IL-8 secretion were significantly elevated in patients with ALF compared to patients with AH and the HC subjects, as expected. The literature describes that the NK cells have an important role in liver damage during non-viral-induced liver diseases and contribute to ALF progression\[[@B7],[@B33]\].

The relative weaknesses of our study included the variance in the plasma cytokine levels, the age of the patients, and the timing of sampling during the evolution of the disease. To minimize the effect of time on our analysis, the blood collection was performed considering the clinical manifestations in self-limited AH and the time of liver failure diagnosis and hospital admission for ALF patients. The sample size was small because the participants who were in the acute symptomatic phase (including pain and malaise) had to agree to the collection of additional samples for cellular immune response investigation; many patients did not return to the ambulatory clinic after resolution of their infection, hindering longitudinal assessment.

In conclusion, The increase of systemically released inflammatory and anti-inflammatory products is associated with AH and ALF. mtDNA and IL-10 may be useful clinical markers as part of a panel to indicate viral (HAV) and non-viral liver disease outcome. These markers, along with IL-8, may be useful to predict death. The anergic behavior of mononuclear cells in fulminant hepatitis A may, in part, be a consequence of the predominant TReg influence that is exclusively detected in HAV infection. Taken together, our results provide additional information to understand the complex immunological disturbances presented during ALF syndrome. Additional efforts are necessary to clarify the anergy mechanism in HAV infection.
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